Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026

Annovis Bio (NYSE: ANVS) will participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026 in November.

Rhea-AI Summary

Annovis Bio (NYSE: ANVS) will participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026 in November. Founder, President and CEO Maria Maccecchini will join a panel and present company updates at U.S. Biotech Day in Philadelphia on November 16; the event runs November 16–17. Her panel will discuss translating discovery-stage insights into clinical proof.

At Pharma Partnering Summit in Boston, running November 19–20, she will present Annovis’ clinical progress on November 19. Maccecchini will also hold one-on-one meetings with industry leaders during both events.

Key Terms

phase 3, proteostasis

2 terms

phase 3 medical

"a Phase 3 clinical-stage biotechnology company"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

proteostasis medical

"Restoring Proteostasis in Alzheimer’s and Parkinson’s Diseases"

Proteostasis is the set of cellular systems that make, fold, repair and remove proteins so they work correctly, like a factory’s quality-control and housekeeping teams keeping machines running. It matters to investors because therapies that fix or alter proteostasis can treat diseases caused by damaged or misfolded proteins, driving clinical trial outcomes, regulatory decisions and the commercial value of biotech companies developing those treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updates

MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that Maria Maccecchini, PhD, Founder, President and CEO of Annovis, will participate and present in two industry events in November.

U.S. Biotech Day 2026 | November 16–17, 2026 | Philadelphia, PA

• Panel: “Bridging the Translational Gap: From Discovery Insights to Clinical Proof”, November 16, 9:15–9:45 a.m. ET
• Company showcase: November 16, 10:15–10:30 a.m. ET

At U.S. Biotech Day 2026, Dr. Maccecchini will join a panel of leaders from Pfizer, Merck, Bristol Myers Squibb, Boehringer Ingelheim and other pharmaceutical companies to discuss how discovery-stage insights translate into clinical proof. She will also deliver a company presentation highlighting Annovis’ clinical programs and upcoming milestones.

Pharma Partnering Summit 2026 | November 19–20, 2026 | Boston, MA

• Company presentation: “Restoring Proteostasis in Alzheimer’s and Parkinson’s Diseases with Buntanetap, a Translational Inhibitor of Neurotoxic Proteins”, November 19, 11:25–11:55 a.m. ET
  

At Pharma Partnering Summit 2026, Dr. Maccecchini will present Annovis’ clinical progress and meet with biotech and pharma representatives.

During both events, Dr. Maccecchini will also hold one-on-one meetings with industry leaders. Attendees interested in scheduling a meeting may do so through each event’s partnering system or by contacting us at ir@annovisbio.com.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com